LEADER 00911nam0-22003131i-450-
001 990006807190403321
005 20001010
035   $a000680719
035   $aFED01000680719
035   $a(Aleph)000680719FED01
035   $a000680719
100   $a20001010d--------km-y0itay50------ba
101 0 $aita
105   $ay-------001yy
200 1 $a<<Gli >>APPALTI pubblici in Europa$eguida pratica e normativa comunitaria e nazionale in tema di$eappalti publici di forniture ..$f(A cura di) Giancarlo Forti.
205   $a2. ed.
210   $aMilano$cPirola$d1994.
215   $aXVIII, 686 p.$d24 cm
225 1 $aAppalti$v
676   $a341.75
702  1$aForti,$bGiancarlo
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990006807190403321
952   $aIII T 211$b25543$fFSPBC
959   $aFSPBC
996   $aAPPALTI pubblici in Europa$9633254
997   $aUNINA
DB    $aGEN01

LEADER 02611nam  2200613 a 450 
001 9910457246603321
005 20200520144314.0
010   $a1-283-21345-1
010   $a9786613213457
010   $a0-309-21222-7
035   $a(CKB)2550000000043073
035   $a(EBL)3378800
035   $a(SSID)ssj0000537170
035   $a(PQKBManifestationID)11352570
035   $a(PQKBTitleCode)TC0000537170
035   $a(PQKBWorkID)10553842
035   $a(PQKB)11052430
035   $a(MiAaPQ)EBC3378800
035   $a(Au-PeEL)EBL3378800
035   $a(CaPaEBR)ebr10488621
035   $a(CaONFJC)MIL321345
035   $a(OCoLC)923283605
035   $a(EXLCZ)992550000000043073
100   $a20110827d2011      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aGlutamate-related biomarkers in drug development for disorders of the nervous system$b[electronic resource] $eworkshop summary /$fDiana E. Pankevich, Miriam Davis, and Bruce M. Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board of Population Health and Public Health Practice, Institute of Medicine of the National Academies
210   $aWashington, D.C. $cNational Academies Press$d2011
215   $a1 online resource (74 p.)
300   $aDescription based upon print version of record.
311   $a0-309-21221-9 
320   $aIncludes bibliographical references and index.
327   $a""Front Matter""; ""Reviewers""; ""Contents""; ""1 Introduction""; ""2 Overview of the Glutamatergic System""; ""3 Glutamate Biomarkers""; ""4 Treatment Implications of Biomarkers""; ""5 Challenges and Opportunities""; ""Appendix A: References""; ""Appendix B: Registered Attendees""; ""Appendix C: Agenda""
606   $aGlutamic acid$xPharmacokinetics
606   $aCentral nervous system$xDiseases
608   $aElectronic books.
615  0$aGlutamic acid$xPharmacokinetics.
615  0$aCentral nervous system$xDiseases.
676   $a616.8061
701   $aPankevich$b Diana E$0856947
701   $aDavis$b Miriam$0856948
701   $aAltevogt$b Bruce M$0856949
712 02$aInstitute of Medicine (U.S.).$bForum on Neuroscience and Nervous System Disorders.
712 02$aInstitute of Medicine (U.S.).$bBoard of Population Health and Public Health Practice.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910457246603321
996   $aGlutamate-related biomarkers in drug development for disorders of the nervous system$91913742
997   $aUNINA

LEADER 01381nam  2200397Ia 450 
001 996385674903316
005 20240530120739.0
035   $a(CKB)1000000000610581
035   $a(EEBO)2240906889
035   $a(OCoLC)9919915600971
035   $a(EXLCZ)991000000000610581
100   $a19890815d1638      uy         |
101 0 $aeng
135   $aurbn#|||a|bb|
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 14$aThe ansvveres of some brethren of the ministerie $eto the replyes of the ministers and professours of divinitie in Aberdeene, concerning the late convenant
210   $a[Edinburgh?] printed$c[J. Wreittoun?]$d1638
215   $a[44] p
300   $aSigned at end: Master Alexander Hamilton, Master David Dickson.
300   $aImprint suggested by STC (2nd ed.).
300   $aSignatures: [pi]² *⁴ [A]²(-A1) B-I².
300   $aReproduction of original in the Harvard University Library.
330   $aeebo-0062
606   $aCovenanters
615  0$aCovenanters.
700   $aHenderson$b Alexander$f1583?-1646.$01003757
701   $aDickson$b David$f1583?-1663.$01001956
702   $aWreittoun$b John$f-1640,
801  1$bEBK
801  2$bWaOLN
906   $aBOOK
912   $a996385674903316
996   $aThe ansvveres of some brethren of the ministerie$92371208
997   $aUNISA